Bristol Myers Squibb (NYSE:BMY) will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 a share.The deal represents an 88% premium to the closing price ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024.

Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb. Bristol Myers is paying $5 a share in cash for 2seventy ...

2seventy bio (NASDAQ:TSVT – Get Free Report)‘s stock had its “sell (e+)” rating reaffirmed by stock analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286 million. The $5.00-per-share offer – announced ...

Write to [email protected] 2seventy bio NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded ...

2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstanding shares ...

2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. “2024 was a pivotal year for 2seventy as ...